32-year-old patient with acute myocardial infarction possibly induced by the appetite suppressant sibutramine;32-jährige Patientin mit akutem Myokardinfarkt der Hinterwand unter Einnahme des Appetitzglers Sibutramin

Deutsche Medizinische Wochenschrift

Volumn 135, Issue 19, 2010, Pages 965-968

  Poss J ^a   Bohm M ^a   Link, A ^a  

^a Klinik Fr Innere Medizin III   (Germany)

Author keywords

Amphetamine derivatives; Coronary artery spasm; Myocardial infarction; Sibutramine

Indexed keywords

AMLODIPINE; RAMIPRIL; SIBUTRAMINE;

ACUTE HEART INFARCTION; ADULT; ANGIOCARDIOGRAPHY; ARTICLE; BODY MASS; CASE REPORT; CORONARY ARTERY; CORONARY ARTERY SPASM; ELECTROCARDIOGRAM; HEART MUSCLE ISCHEMIA; HUMAN; HYPOKINESIA; LABORATORY TEST; OBESITY; PHYSICAL EXAMINATION; ST SEGMENT DEPRESSION; T WAVE INVERSION; THORAX PAIN;

EID: 77952087120     PISSN: 00120472     EISSN: 14394413     Source Type: Journal    
DOI: 10.1055/s-0030-1253684     Document Type: Article

References (11)

1. Azarisman S M., Magdi Y A., Noorfaizan S, Oteh M. Myocardial infarction induced by appetite suppressants in Malaysia. N Engl J Med 2007 357 1873-1874
2. Bundesinstitut fr Arzneimittel und Medizinprodukte. http://www.bfarm.de/ cln-012/nn-424276/DE/BfArM/Presse/mitteil2010/pm012010.html--nnn=trueLetzter Zugriff: 21.01.2010
3. Eroglu E, Gemici G, Bayrak F, Kalkan A K., Degertekin M. Acute myocardial infarction in a 24 year-old man possibly associated with sibutramine use. Int J Cardiol 2009 137 e43-45
4. Europäische Arzneimittelagentur. European Medicines Agency recommends suspension of marketing authorisations for sibutramin. http://www.ema.europa.eu/pdfs/human/referral/sibutramine/3940810en.pdf Letzter Zugriff: 19.4.2010
5. Finer N. Sibutramine: its mode of action and efficacy. Int J Obes Relat Metab Disord 2002 26 Suppl 4 S29-33
6. Food and Drug Administration. Early Communication about an Ongoing Safety Review of Meridia (sibutramine hydrochloride). http://www.fda.gov/Drugs/ DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ DrugSafetyInformationforHeathcareProfessionals/ucm191650.htm Letzter Zugriff: 19.4.2010
7. Heal D J., Aspley S, Prow M R. et al. Sibutramine: a novel anti-obesity drug. A review of the pharmacological evidence to differentiate it from d-amphetamine and d-fenfluramine. Int J Obes Relat Metab Disord 1998 22 Suppl 1 S18-28
8. Heal D J., Cheetham S C., Prow M R., Martin K F., Buckett W R. A comparison of the effects on central 5-HT function of sibutramine hydrochloride and other weight-modifying agents. Br J Pharmacol 1998 125 301-308
9. Padwal R S., Majumdar S R. Drug treatments for obesity: orlistat, sibutramine, and rimonabant. Lancet 2007 369 71-77
10. Torp-Pedersen C, Caterson I, Coutinho W et al. Cardiovascular responses to weight management and sibutramine in high-risk subjects: an analysis from the SCOUT trial. Eur Heart J 2007 28 2915-2923
11. Yim K M., Ng H W., Chan C K., Yip G, Lau F L. Sibutramine-induced acute myocardial infarction in a young lady. Clin Toxicol (Phila) 2008 46 877-879